AUTHORS
Bilgimol Chumappumkal Joseph, PhD, Juan Andrés De Pablo-Moreno, PhD2, Nicca Falah, BS3, Mia Lora Cacho, BS4, Ryan Mathew, BS5, Abe Wentzel, BS6, Annette von Drygalski Jr, MD, PharmD7
AFFILIATIONS
1 University of California San Diego, La Jolla, California, United States
2 Universidad Complutense de Madrid, Madrid, Madrid, Spain, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain
3 University of California San Diego, La Jolla, California, United States
4 University of California San Diego, La Jolla, California, United States
5 University of California San Diego, La Jolla, California, United States
6 University of California San Diego, La Jolla, California, United States
7 University of California San Diego, La Jolla, California, United States
ABSTRACT
Abstract
Introduction
Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality, with acute obstetric coagulopathy (AOC) contributing to poor outcomes. Mechanistic determinants of AOC remain poorly defined. We developed murine models of obstetric vascular injury to characterize coagulation-fibrinolysis dynamics and evaluate tranexamic acid (TXA) efficacy.
Methods
Pregnant C57BL/6J mice (gestational day [GD] 18) underwent disruption of spiral arteries (SA) adjacent to the placental bed or the uterine artery (UA). Baseline hematologic indices, tissue iron concentrations, and coagulation parameters were obtained from nonpregnant and GD17 mice. Blood loss, coagulation parameters (activated partial thromboplastin time [aPTT], coagulation factor [F] activities (FV, FVIII, FII, FX), thrombin generation (thrombin anti-thrombin [TAT] complexes), and fibrinolysis (fibrinogen, FXIIIb, plasmin anti-plasmin [PAP] complexes, D-dimer, urokinase-type plasminogen activator [uPA], and tissue-type plasminogen activator [tPA]) were assessed at 60 minutes post SA or UA injury. TXA (10 mg/kg) was administered five minutes before injury.
Results
Late gestation showed physiologic anemia and thrombocytosis with reduced hepatic iron and increased fetal/placental iron, consistent with active maternal–fetal iron transfer. Pregnancy established a procoagulant baseline with elevated FV (361%), FII (200%), and FX (180%).
SA injury caused modest hemorrhage (13 µL/g), whereas UA injury produced greater blood loss (28 µL/g), reduced by TXA (15 µL/g). Both models induced acute coagulopathy with aPTT prolongation (SA: 30 s; UA: 37 s vs baseline: 23 s), which was normalized only in SA by TXA (23 s).
Both injury models triggered marked thrombin generation (TAT: SA, 1173 ng/mL; UA, 1274 ng/mL), which was attenuated by TXA (153 and 185 ng/mL, respectively). This was accompanied by reductions in FV (baseline, 361%; SA, 213%; UA, 130%), FVIII (SA, 63%; UA, 26%), fibrinogen (~40% reduction in both models), and circulating FXIIIb antigen (SA, 13%; UA, 17%). TXA substantially suppressed thrombin generation and normalized FVIII and fibrinogen but did not restore FV or circulating FXIIIb antigen. FII remained preserved, whereas FX exhibited injury- and treatment-dependent changes.
PAP complexes were significantly increased (SA 650; UA 763 ng/mL) and reduced by TXA. uPA and tPA were unchanged. D-dimer elevation occurred only in UA injury (71 ng/mL) and normalized with TXA (33 ng/mL).
Correlation analysis demonstrated a pattern consistent with consumptive coagulopathy: TAT inversely correlated with fibrinogen (r = −0.84) and circulating FXIIIb antigen (r = −0.77), while FXIIIb antigen correlated positively with fibrinogen (r = 0.85).
Uterine artery injury resulted in 22% mortality within 20 minutes, which was completely prevented by TXA.
Conclusion
These murine models recapitulate key features of human AOC including rapid thrombin generation, early fibrinogen depletion, fibrinolysis, and reduced FXIII. Together, these findings establish a translational platform for investigating AOC mechanisms and novel therapies for PPH.
DISCLOSURES
Bilgimol Chumappumkal Joseph, PhD: No relevant conflicts of interest to declare.